Epigenomics, Wuhan Kindstar Ink Deal for Lung Cancer Assay in China | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenomics and Wuhan Kindstar Clinical Diagnostics today announced a licensing and supply deal for the Epi proLung tissue assay for the Chinese market.

The terms of the deal call for Kindstar to commercialize Epigenomics' assay, while the Berlin-based company will manufacture and supply it. Epigenomics also will provide support "with respect to medical and regulatory considerations."

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.